100 results
8-K
EX-99.1
ALLK
Allakos Inc
28 May 24
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
7:15am
additional product candidates beyond AK006; uncertainties related to Allakos’ ability to realize the contemplated benefits of its restructuring
8-K
EX-99.1
ALLK
Allakos Inc
9 May 24
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
4:06pm
benefits of its restructuring and related reduction in force; Allakos’ ability to accurately forecast financial results; Allakos’ ability to obtain
8-K
EX-99.1
w4dgcr320f9y1na 7h
14 Mar 24
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:15pm
8-K
EX-99.1
qyhwr jfz
26 Feb 24
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
7:05am
8-K
EX-99.1
vdshf1l6
12 Feb 24
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
7:07am
8-K
EX-99.1
rxx1 o0rd
16 Jan 24
Regulation FD Disclosure
6:17pm
8-K
EX-99.1
c4nqwtd
16 Jan 24
Allakos Announces a Restructuring to Focus on Development of AK006
5:00pm
424B5
7gztwf49s8o14
19 Sep 22
Prospectus supplement for primary offering
7:32am
8-K
EX-1.1
7ruohlu4zlkmhe td
19 Sep 22
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
7:14am
8-K
EX-99.2
jjnf hvxgfwdp96dtg
19 Sep 22
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
7:14am
8-K
EX-1.1
1wcmpc rzdlq5j9rtn4
4 Aug 22
Entry into a Material Definitive Agreement
5:31pm